Interest in compounded drugs has grown rapidly, with compounded peptides now playing a visible role alongside FDA-approved therapies. While lawful and strategic opportunities exist, careful navigation of an evolving regulatory environment is essential to avoid state board of pharmacy scrutiny or FDA and FTC enforcement.
Frier Levitt attorneys Edgar Asebey and Guilherme Ferrari Faviero discuss the outlook on peptide regulation in their Dispense Times article, “Peptide Regulation in 2026: What You Need to Know to Remain Compliant.” The article examines the regulatory framework governing peptide products and the current U.S. peptide market. While enforcement activity is expected to increase in 2026, well-advised and compliant operators may still find meaningful opportunities in the year ahead. As regulations continue to evolve, access to real-time, reliable regulatory guidance is critical to ensure compliance.
Access the full Dispense Times January-February 2026 Issue (article found on page 20): Dispense Times
Senior Associate
